Bukwang Pharmaceutical Co., Ltd. (KRX: 003000)

Market Cap	304.62B
Revenue (ttm)	116.58B
Net Income (ttm)	-31.55B
Shares Out	68.45M
EPS (ttm)	-459.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	139,279
Open	4,310.00
Previous Close	4,335.00
Day's Range	4,255.00 - 4,395.00
52-Week Range	4,255.00 - 9,000.00
Beta	-0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About Bukwang Pharmaceutical

Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, liver cirrhosis, and iron-deficiency anemia; over-the-counter drugs, such as fever and pain relief medication, gastrointestinal medication, cold medication...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1960
• Employees: 554
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 003000

Financial Performance

In 2023, Bukwang Pharmaceutical's revenue was 125.93 billion, a decrease of -34.04% compared to the previous year's 190.91 billion. Losses were -31.33 billion, 1165.9% more than in 2022.